Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 10793 - 10800 of 12140 results
Updated: New York City Looks to Expand its Paid Sick Leave Law Before it Takes Effect in April 2014
January 22, 2014| Blog| Viewpoint
What Do the Proposed Changes to Medicare Parts C and D Mean For Your Business?
January 22, 2014| Blog| Viewpoint
MA Appeals Court Narrows but Otherwise Keeps Intact Individual Liability Under the Wage Act
January 21, 2014| Blog| Viewpoint
The Affordable Care Act—Countdown to Compliance for Employers, Week 49: Waiting for the Final Code Section 4980H Regulations
January 21, 2014| Blog| Viewpoint
Why A-Rod Faces Long Odds in His Attempt to Overturn the Grievance Arbitration Award
January 21, 2014| Blog| Viewpoint
Look North, Marketers - Canadian Anti-Spam Law is Coming
January 21, 2014| Blog| Viewpoint
ML Strategies Posts Weekly Health Care Reform Update on January 21, 2014
January 21, 2014| Blog| Viewpoint
CMS Proposes Major Changes to Medicare Parts C and D
January 21, 2014| Advisory| Viewpoint
News & Press Releases
Mintz Advises Charlesbank Capital Partners on Acquisition of Q6 Cyber
September 15, 2025
Mintz Advises on LB Pharmaceuticals’ $285 Million Initial Public Offering
September 12, 2025
Mintz advised the underwriters in connection with a $285 million initial public offering by LB Pharmaceuticals Inc of 19,000,000 shares of common stock at an initial public offering price of $15.00 per share. The aggregate gross proceeds to LB Pharmaceuticals from this offering were approximately $285 million before deducting underwriting discounts and commissions and other offering expenses. In addition, LB Pharmaceuticals granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Market on September 11, 2025 under the ticker symbol “LBRX.”
Mintz Advises the Placement Agents in CAMP4’s up to $100 Million Private Placement
September 12, 2025
Mintz advised the placement agents in connection with CAMP4's up to $100 million private placement. The private placement included upfront gross proceeds of $50 million in exchange for common stock (and pre-funded warrants in lieu of common stock for certain investors). In addition, CAMP4 will be eligible to receive up to an additional $50 million in gross proceeds in exchange for common stock (and pre-funded warrants for certain investors), subject to achieving pre-specified milestones, including receipt of regulatory clearance to initiate a Phase 1/2 clinical trial in SYNGAP patients with its development candidate, CMP-SYNGAP-01.
Events
Podcasts
Mintz On Air: Practical Policies – Disparage Me Not
August 26, 2025| Podcast|
Mintz On Air: Practical Policies - Investigations Unscripted
August 12, 2025| Podcast|
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|